This trial will assess safety and how ABBV-552 moves through the body of 18 adult healthy Japanese & Han Chinese volunteers. Adverse Events will be monitored.
11 Primary · 0 Secondary · Reporting Duration: Up to approximately 45 days
2 Treatment Groups
Arm 1: Healthy Japanese Participants
1 of 2
Arm 2: Healthy Han Chinese Participants
1 of 2
18 Total Participants · 2 Treatment Groups
Primary Treatment: Arm 1: Healthy Japanese Participants · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 55 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the arm of this study involving healthy Japanese individuals been approved by the FDA?
"The safety of Arm 1: Healthy Japanese Participants is estimated at a score of 1 due to the lack of data regarding efficacy and safety, as this is an experimental Phase one trial." - Anonymous Online Contributor
Who qualifies for enrollment in this medical experiment?
"Qualifying individuals should be healthy adults in the 18 to 55 age range, and this study aims to recruit roughly 18 participants." - Anonymous Online Contributor
Are participants at least 85 years of age eligible for this exploration?
"Eligible participants in this medical study must be between 18 and 55 years old." - Anonymous Online Contributor
Does this research currently have open enrollment?
"This clinical trial, which was initially shared on January 17th 2023 and recently updated on the 13th of this month, is actively looking for participants. This information can be found on clinicaltrials.gov." - Anonymous Online Contributor
What is the total enrollment of this research project?
"That is correct. According to the clinicaltrials.gov platform, this medical investigation has been recruiting since January 17th 2023 and was last updated on January 13th 2023. Currently, 18 participants are needed across two distinct research centres." - Anonymous Online Contributor